Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment
Open Access
- 6 July 2021
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (11), e29204
- https://doi.org/10.1002/pbc.29204
Abstract
Background Oral etoposide is commonly used in palliative treatment of childhood and young adult cancer without robust evidence. We describe a national, unselected cohort of young people in England treated with oral etoposide using routinely collected, population-level data. Methods Patients aged under 25 years at cancer diagnosis (1995–2017) with a treatment record of single-agent oral etoposide in the Systemic AntiCancer Dataset (SACT, 2012–2018) were identified, linked to national cancer registry data using NHS number and followed to 5 January 2019. Overall survival (OS) was estimated for all tumours combined and by tumour group. A Cox model was applied accounting for age, sex, tumour type, prior and subsequent chemotherapy. Results Total 115 patients were identified during the study period. Mean age was 11.8 years at cancer diagnosis and 15.5 years at treatment with oral etoposide. Median OS was 5.5 months from the start of etoposide; 13 patients survived beyond 2 years. Survival was shortest in patients with osteosarcoma (median survival 3.6 months) and longest in CNS embryonal tumours (15.5 months). Across the cohort, a median of one cycle (range one to nine) of etoposide was delivered. OS correlated significantly with tumour type and prior chemotherapy, but not with other variables. Conclusions This report is the largest series to date of oral etoposide use in childhood and young adult cancer. Most patients treated in this real world setting died quickly. Despite decades of use, there are still no robust data demonstrating a clear benefit of oral etoposide for survival.This publication has 26 references indexed in Scilit:
- Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label studyJournal of Neuro-Oncology, 2016
- Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trialsThe Lancet Oncology, 2014
- Recurrent intracranial ependymoma in children: salvage therapy with oral etoposidePediatric Neurology, 2001
- Phase II study of 21 day schedule oral etoposide in childrenEuropean Journal of Cancer, 1997
- Recurrent Supratentorial Malignant Gliomas in ChildrenArchives of Neurology, 1997
- Recurrent Cerebellar Gliomas: Salvage Therapy With Oral EtoposideJournal of Child Neurology, 1997
- Response of recurrent medulloblastoma to low-dose oral etoposide.Journal of Clinical Oncology, 1996
- Recurrent Chiasmatic-Hypothalamic Glioma Treated With Oral EtoposideArchives of Neurology, 1995
- 21-day schedule oral etoposide in children— a feasibility studyEuropean Journal of Cancer, 1993
- Recurrent brainstem gliomas treated with oral VP-16Journal of Neuro-Oncology, 1993